PEAR THERAPEUTICS ANNOUNCES AGREEMENT WITH IRONWOOD PHARMACEUTICALS TO EVALUATE PRESCRIPTION DIGITAL THERAPEUTICS FOR PATIENTS WITH GI INDICATIONS
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Pear deepens its Prescription Digital Therapeutics (PDTs) pipeline and expands its platform outside of brain-related conditions
- Companies to explore developing PDTs for the treatment of patients with selected indications within the gastrointestinal (GI) space
- Collaboration combines Pear?s expertise in PDTs with Ironwood?s GI franchise and clinical development expertise?